Project Grant R43CA235823

This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...

This federal Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $427,392.00 to The Leland Stanford Junior University to develop a small molecule called SHC301 that inhibits Src Homology and Collagen (SHC) signaling, a non-canonical TGF-β pathway, for the treatment of transplant-related pulmonary fibrosis. The award supports preclinical studies to assess the efficacy of SHC301 in human precision cut lung slices and a mouse orthotopic...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $464,121 to The Medical University of South Carolina to develop peptides derived from collagen XVIII for the treatment of pulmonary fibrosis. The project aims to simultaneously test the identified peptides in preclinical models of fibrosis, identify a lead candidate, characterize its efficacy, conduct dose escalation...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,193,262 to The Regents of the University of California, San Francisco to develop an adeno-associated virus-mediated SGPL1 gene therapy as a potential first-in-class treatment for idiopathic pulmonary fibrosis (IPF). The research aims to confirm the efficacy of this gene therapy in reducing lung fibrosis and downstream profibrotic signaling in mouse models and...

The University of Pittsburgh has been awarded a $325,950 project grant from the National Institute on Aging's Aging Research program (CFDA 93.866) to conduct research on preventing pulmonary fibrosis. The research aims to establish that the tyrosine kinase protein FGR, which is induced in senescent lung cells, initiates pulmonary fibrosis by secreting proinflammatory proteins and recruiting inflammatory cells. The project will use mouse models to confirm the role of FGR in pulmonary fibrosis and...

The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel oral small molecule therapeutics for the treatment of progressive pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). The goal is to create a safer and more effective therapy compared to the currently approved drugs, which only slow disease progression and have significant side effects. Novomedix will...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding research at Northwestern University to investigate the role of mitochondrial metabolism in alveolar epithelial cell differentiation and the development of lung fibrosis. The $616,000 award, effective September 1, 2024 through August 31, 2029, will support experiments using genetic mouse models to determine how mitochondrial...

The University of Kentucky Research Foundation received a $698,070 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on targeting lung fibrosis using epigenetic therapy. The 4-year project, which commenced on August 15, 2024, aims to examine whether the FDA-approved EZH2 inhibitor Tazemetostat can prevent or reverse aberrant epithelial cell fate and pro-fibrotic signaling in organotypic cell cultures and in...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...

This federal Project Grant award of $805,845 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and testing of novel lung-targeted therapeutic delivery systems. The goal is to create "precision drug delivery systems" that can actively transport anti-fibrotic agents directly into lung tissue to treat conditions like idiopathic pulmonary fibrosis. Key products/services include engineering...